Table 2

Dose of dendritic cells (APC8015) and soluble antigen (PA2024) delivered to patients

PatientDendritic cells (CD54+; 106/m2)aPA2024 (mg/dose)
Infusion no. 1Infusion no. 2
1–3248 ± 86306 ± 2370.3
4–6230 ± 140147 ± 490.6
7–13b325 ± 155217 ± 1281.0
  • a No difference among groups was statistically significant.

  • b Patient 7 received one dose of dendritic cells and no PA2024 because of early disease progression. Patients 5 and 8 received only one dose of PA2024, and patients 9 and 12 received only two doses.